May 10, 2023 / 10:40PM GMT
Alec Warren Stranahan - BofA Securities, Research Division - Associate
Hey, everyone. Good afternoon, and welcome to day 2 of the 2023 BofA Healthcare Conference. Thanks for joining the session with HUTCHMED. My name is Alec Stranahan. I'm Vice President and senior biotech analyst covering HUTCHMED here at BofA. And I'm pleased to be joined by Mark -- Mike, who's the CMO of HUTCHMED. And I think Mike's going to give some prepared remarks to set the stage, and then we'll jump into Q&A. So over to you Mike.
Ming Shi - HUTCHMED(China)Limited-Executive VP - Head of R&D and Chief Medical Officer
Yes. Thank you, Alec. Yes, it's a great pleasure to be here. And I just want to have a few words about HUTCHMED, is a biotech company based -- headquartered in Hong Kong. It's been for 20 years, and we have three products already marketed in China, savolitinib, fruquintinib and surufatinib. And we also have a full integrated discovery, development and the commercial pipeline in China. In -- extra China side,
HUTCHMED (China) Ltd at Bank of America Global Healthcare Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot